Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Place a direct purchase order on this report @ http://www.orbisresearch.com/contact/purchase/148564 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Request a sample of Myelodysplastic Syndrome – Pipeline Review, H2 2016
– The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
– The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acceleron Pharma Inc
Actinium Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
Altor BioScience Corp
Ariad Pharmaceuticals Inc
Arno Therapeutics Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Astex Pharmaceuticals Inc
Atara Biotherapeutics Inc
Bellicum Pharmaceuticals Inc
Bio-Path Holdings Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Cantex Pharmaceuticals Inc
Celldex Therapeutics Inc
Cellerant Therapeutics Inc
Constellation Pharmaceuticals Inc
Cornerstone Pharmaceuticals Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
FORMA Therapeutics Inc
Gamida Cell Ltd
H3 Biomedicine Inc
IGF Oncology LLC
Io Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hansoh Pharmaceutical Co Ltd
Johnson & Johnson
Johnson & Johnson Pharmaceutical Research & Development,
Juno Therapeutics Inc
JW Pharmaceutical Corp
Kainos Medicine Inc
KaloBios Pharmaceuticals Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kyowa Hakko Kirin Co Ltd
La Jolla Pharmaceutical Company
Lixte Biotechnology Holdings Inc
Mateon Therapeutics Inc
MEI Pharma Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Nemucore Medical Innovations Inc
Onconova Therapeutics Inc
OncoTherapy Science Inc
Opsona Therapeutics Ltd
Pharma Mar SA
Regen BioPharma Inc
Rich Pharmaceuticals Inc
Seattle Genetics Inc
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
Teva Pharmaceutical Industries Ltd
Toko Pharmaceutical Industries Co., Ltd.
Tolero Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
Trillium Therapeutics Inc
Browse the complete report @ http://www.orbisresearch.com/reports/index/myelodysplastic-syndrome-pipeline-review-h2-2016 .
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: firstname.lastname@example.org